NASDAQ: PMCB - PharmaCyte Biotech, Inc.

半年間の収益性: -23.79%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール PharmaCyte Biotech, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

さらに詳しく
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2010-09-17
ISIN US71715X2036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://pharmacyte.com
Цена ао 2.44
1日あたりの価格変動: +0.641% (1.56)
週ごとの価格変動: -4.27% (1.64)
月ごとの料金変更: -8.19% (1.71)
3ヶ月間の価格変動: -14.67% (1.84)
半年間の価格変動: -23.79% (2.06)
年間の価格変動: -27.31% (2.16)
3年間の価格推移: -38.67% (2.56)
5年間の価格推移: +4 398.57% (0.0349)
10年間の価格推移: 0% (1.57)
年初からの価格変動: -8.19% (1.71)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 0.514 10
P/E 60.86 1
EV/EBITDA -89.49 0
合計: 3.63

効率

名前 意味 学年
ROA, % 0.5012 1
ROE, % 0.5949 1
合計: 0.3333

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0.0212

義務

名前 意味 学年
Debt/EBITDA 0 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % -98.14 0
収益性 Ebitda, % -108.78 0
収益性 EPS, % -1344.13 0
合計: 0
さらに詳しく

機関 音量 共有, %
K2 Principal Fund, L.P. 304613 0.01
Geode Capital Management, LLC 215637 0.01
Vanguard Group Inc 171335 0.01
Equitec Proprietary Markets LLC 82727 0
Sabby Management, LLC 82373 0
Renaissance Technologies, LLC 38100 0
Dimensional Fund Advisors LP 29307 0
Blackrock Inc. 28769 0
Citadel Advisors Llc 28618 0
Schonfeld Strategic Advisors LLC 23200 0

ETF 共有, % 年間の利益率, % 配当金, %
Dimensional U.S. Targeted Value ETF 0.00013 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.00006 30.76 1.47098



スーパーバイザー 役職 支払い 生年
Mr. Joshua N. Silverman Interim CEO, Interim President & Interim Chairman 197.92k 1970 (55 年)
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 380k 1958 (67 年)
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer N/A 1957 (68 年)
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant N/A

住所: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - Googleマップで開く, Yandexマップを開く
Webサイト: https://pharmacyte.com